CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time to discuss the results. Investors can access the call via telephone using the conference ID CVRXQ225 or through a live webcast available on the company's investor relations website at ir.cvrx.com.
[]CVRx (NASDAQ: CVRX), un'azienda di dispositivi medici operativa a livello commerciale e specializzata in soluzioni di neuromodulazione per le malattie cardiovascolari, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 4 agosto 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 ora della costa orientale per discutere i risultati. Gli investitori potranno partecipare alla chiamata telefonando con l'ID conferenza CVRXQ225 oppure tramite una diretta web disponibile sul sito dedicato alle relazioni con gli investitori all'indirizzo ir.cvrx.com.
CVRx (NASDAQ: CVRX), una empresa de dispositivos médicos en etapa comercial especializada en soluciones de neuromodulación para enfermedades cardiovasculares, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 4 de agosto de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 4:30 PM hora del Este para discutir los resultados. Los inversores pueden acceder a la llamada por teléfono usando el ID de conferencia CVRXQ225 o a través de una transmisión en vivo disponible en el sitio web de relaciones con inversores de la empresa en ir.cvrx.com.
CVRx (NASDAQ: CVRX)는 심혈관 질환을 위한 신경조절 솔루션을 전문으로 하는 상업 단계 의료기기 회사로, 2025년 2분기 재무실적 발표를 2025년 8월 4일 장 마감 후에 예정하고 있습니다.
회사는 동부 표준시 오후 4시 30분에 실적 관련 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 컨퍼런스 ID CVRXQ225를 사용하여 전화로 참여하거나 회사 투자자 관계 웹사이트 ir.cvrx.com에서 라이브 웹캐스트를 통해 접속할 수 있습니다.
CVRx (NASDAQ : CVRX), une société de dispositifs médicaux en phase commerciale spécialisée dans les solutions de neuromodulation pour les maladies cardiovasculaires, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 4 août 2025, après la clôture du marché.
La société organisera une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats. Les investisseurs peuvent accéder à l'appel par téléphone en utilisant l'ID de conférence CVRXQ225 ou via une diffusion en direct disponible sur le site des relations investisseurs de la société à ir.cvrx.com.
CVRx (NASDAQ: CVRX), ein medizinisches Unternehmen in der kommerziellen Phase, das sich auf Neuromodulationslösungen für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 4. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können per Telefon mit der Konferenz-ID CVRXQ225 teilnehmen oder über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens unter ir.cvrx.com zugreifen.
- None.
- None.
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When will CVRx (NASDAQ: CVRX) release its Q2 2025 earnings?
How can investors access the CVRx Q2 2025 earnings call?
What time is the CVRx Q2 2025 earnings conference call?
What does CVRx company do?
